BriaCell Therapeutics (NASDAQ:BCTX) Shares to Reverse Split on Wednesday, January 29th

BriaCell Therapeutics Corp. (NASDAQ:BCTX) shares are going to reverse split on Wednesday, January 29th. The 1-15 reverse split was announced on Friday, January 3rd. The number of shares owned by shareholders will be adjusted after the market closes on Tuesday, January 28th.

BriaCell Therapeutics Price Performance

Shares of NASDAQ:BCTX opened at $0.40 on Friday. The firm has a fifty day moving average price of $0.64 and a two-hundred day moving average price of $0.72. The company has a market cap of $17.54 million, a price-to-earnings ratio of -0.45 and a beta of 1.55. BriaCell Therapeutics has a one year low of $0.37 and a one year high of $4.37.

BriaCell Therapeutics (NASDAQ:BCTX) last issued its quarterly earnings data on Monday, December 16th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.14). Equities research analysts expect that BriaCell Therapeutics will post -1.01 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and set a $15.00 price objective on shares of BriaCell Therapeutics in a report on Thursday, December 12th.

Institutional Trading of BriaCell Therapeutics

An institutional investor recently bought a new position in BriaCell Therapeutics stock. Vontobel Holding Ltd. purchased a new position in BriaCell Therapeutics Corp. (NASDAQ:BCTX) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 80,000 shares of the company’s stock, valued at approximately $99,000. Vontobel Holding Ltd. owned about 0.44% of BriaCell Therapeutics as of its most recent SEC filing. 15.42% of the stock is currently owned by institutional investors and hedge funds.

About BriaCell Therapeutics

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.